| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4028957 | Ophthalmology | 2007 | 15 Pages |
Abstract
These results demonstrate that intravitreal bevacizumab can reduce DME in some eyes, but the study was not designed to determine whether treatment is beneficial. A phase III trial would be needed for that purpose.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Diabetic Retinopathy Clinical Research Network Diabetic Retinopathy Clinical Research Network,